Deutsche Bank AG Acquires 73,213 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Deutsche Bank AG increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 226.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,583 shares of the specialty pharmaceutical company’s stock after purchasing an additional 73,213 shares during the quarter. Deutsche Bank AG’s holdings in Supernus Pharmaceuticals were worth $3,818,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets increased its position in Supernus Pharmaceuticals by 248.0% in the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock valued at $10,581,000 after acquiring an additional 208,552 shares in the last quarter. Raymond James Financial Inc. bought a new position in Supernus Pharmaceuticals during the 4th quarter worth approximately $6,847,000. Great Lakes Advisors LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter worth approximately $6,131,000. D. E. Shaw & Co. Inc. boosted its stake in Supernus Pharmaceuticals by 33.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company’s stock worth $19,731,000 after acquiring an additional 136,870 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its stake in Supernus Pharmaceuticals by 944.2% in the fourth quarter. Cubist Systematic Strategies LLC now owns 139,522 shares of the specialty pharmaceutical company’s stock valued at $5,045,000 after buying an additional 126,161 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on SUPN shares. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $33.05 on Tuesday. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The company has a market cap of $1.85 billion, a P/E ratio of 30.89 and a beta of 0.74. The firm’s fifty day moving average price is $31.92 and its two-hundred day moving average price is $34.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.